

CASE REPORT

Open Access



The value of the portable fibrinogen measuring device—a case report of severe postpartum hemorrhage with obstetric disseminated intravascular coagulation

Yoko Hikida¹, Hiroyuki Sumikura¹, Hisako Okada^{2*} , Takashi Fujino¹, Mayumi Tanaka¹, Yu Sakai³, Shoko Okahara¹ and Rie Inoue¹

Abstract

Background: Fibrinogen concentration is an important indicator of the treatment for obstetric disseminated intravascular coagulation (DIC). We present how using the fibrinogen measuring device could solve problems in the treatment of postpartum hemorrhage with complicated DIC.

Case presentation: A 32-year-old woman with monochorionic diamniotic twins at 22 weeks of pregnancy was diagnosed with placental abruption and underwent emergent cesarean section. The estimated blood loss was 8375 g. She was transferred to our hospital for further treatment. Compressive uterine sutures and balloon tamponade were performed. We transfused fibrinogen and fresh frozen plasma actively during the operation to maintain plasma fibrinogen above 200 mg/dL by using a point-of-care fibrinogen measuring device. In spite of massive hemorrhage exceeding 10 L, she was extubated at the end of the operation and discharged on the 7th day after the operation.

Conclusion: The portable fibrinogen measuring device was useful for point-of-care assessment of obstetric DIC.

Keywords: Postpartum hemorrhage, Obstetric disseminated intravascular coagulation, Fibrinogen, Point-of-care device, Obstetric anesthesia

Background

Postpartum hemorrhage (PPH), which rapidly develops acquired hypofibrinogenemia and/or disseminated intravascular coagulation (DIC), is one of the leading causes of maternal mortality. Fibrinogen concentration has been increasingly recognized as an important indicator of the treatment for PPH [1, 2]. Recently, a Japanese manufacturer (A&T Corporation) developed a portable device (CG02N[®]) that enables point-of-care fibrinogen measurement. We had previously reported a case in

which the device was successfully used for the management of massive PPH [3]. In what follows, we present another case where the portable fibrinogen measuring device was useful for the treatment of PPH with more complicated obstetric DIC.

Case presentation

A 32-year-old woman (157 cm, 47.9 kg, 3 gravida, 2 para) was referred to our hospital due to PPH. She has had a history of 2 previous cesarean deliveries for labor arrest and intrauterine fetal demise. In her third pregnancy, monochorionic diamniotic twins were diagnosed. At 22 weeks of pregnancy, however, the patient was diagnosed with placental abruption and underwent category-1 emergent cesarean section at the previous hospital.

* Correspondence: h-okada@juntendo.ac.jp

²Department of Anesthesiology and Pain Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan

Full list of author information is available at the end of the article

The operation was started under general anesthesia. Her preemie babies were successfully delivered and taken care of by neonatologists. Due to placental abruption, she was suffered from atonic bleeding and coagulopathy. Balloon tamponade with Bakri balloon® was performed before completion of the surgery. However, vaginal bleeding without clot formation continued after surgery in spite of procoagulant supplementation with fresh frozen plasma (FFP). Despite administering 2 mg of recombinant activated factor VII (rFVIIa) and 3000 international units (IU) of freeze-dried concentrated human antithrombin, the estimated blood loss increased to 8375 g. The total amount of transfusion reached to 26 units of packed red blood cells (PRBCs), 30 units of FFP, and 20 units of platelets. The patient was transferred to our hospital for further treatment.

Upon her arrival at our hospital, her blood pressure was 109/89 mmHg, heart rate was 135 bpm (shock index was 1.23), and she was conscious. Continuous bleeding without clotting out of her vagina was found. Along with blood sampling for ordinal laboratory tests, we measured fibrinogen concentration using a portable fibrinogen measuring device at the point of care. It showed 250 mg/dL, with which we judged that her coagulability was tolerable for surgical procedure. Accordingly, we decided to perform another surgery to control her bleeding instead of an arterial embolization by interventional radiology. Laboratory-based test later showed that her plasma fibrinogen level prior to the operation was 243 mg/dL, which matched very well to the result of the portable device (Table 1).

Although her fibrinogen concentration seemed to be an acceptable level for surgery, we administered 3 g of freeze-dried human fibrinogen prophylactically to minimize the risk of bleeding. However, this administration increased the fibrinogen value to 258 mg/dL, which was not as much as we had expected. Therefore, we

assessed that her coagulability might be in the hyperfibrinolysis, and decided to transfuse FFP actively during the operation to maintain plasma fibrinogen above 200 mg/dL. We also started to transfuse platelets and PRBCs against low hemoglobin (6.6 g/dL) and platelet counts ($23 \times 10^9/L$) before the operation (Table 1).

After careful induction of general anesthesia, compressive uterine sutures and balloon tamponade were performed effectively to control her bleeding, and she was extubated at the end of the operation.

As a result, additional blood loss during the surgery was 2310 g, and the amount of transfusion was 12 units of PRBCs, 12 units of FFP, and 20 units of platelets at our hospital. In spite of massive hemorrhage (exceeding 10 L), she was discharged on the 7th day after the operation.

Discussion

In the current case, the portable fibrinogen measuring device allowed us to provide timely and appropriate treatment for a patient with complicated obstetric DIC. However, some cautions are necessary in handling this device successfully.

There is a glowing consensus that supplementation of fibrinogen is an important component for the treatment of obstetric DIC and that the conventional laboratory-based coagulation tests can be the problem at the time of providing immediate treatment for obstetric DIC because of its time-consuming nature [4, 5]. And some point-of-care devices for fibrinogen measurement have been developed [6]. Our device measures fibrinogen by way of the process of dry-hematology system. It does not require centrifugation and can measure fibrinogen in a whole blood sample within about a minute [7]. Thus, using this device will allow us to provide timely and appropriate management, as it maintains the minimum level of fibrinogen concentration (if not more)

Table 1 Time course of fibrinogen concentration and laboratory-based test

	Total amount of bleeding (g)	Point-of-care measurement	Laboratory measurement						
		Fib (mg/dL)	Fib (mg/dL)	Hb (g/dL)	Plt ($10^9/L$)	APTT (s)	PT (%)	FDP ($\mu g/mL$)	AT (%)
At arrival	8375	250	243	6.2	23	49.7	97	12.7	66
After administration of 3 g of fibrinogen concentration	–	258	–	–	–	–	–	–	–
After administration of 10 U of FFP, 10 U of RBC and 20 U of platelets	10225	261	–	–	–	–	–	–	–
At the end of operation (after additional administration of 2 U of FFP and 2 U of RBC)	10685	256	203	6.4	50	50	90	40.4	57

Along with blood sampling for ordinal laboratory tests, we measured fibrinogen concentration using a portable fibrinogen measuring device at the point of care. A laboratory-based test later showed that her plasma fibrinogen level prior to the operation was 243 mg/dL, which matched very well to the result of the portable device. The laboratory-based test showed low platelets and hemoglobin. We started to transfuse platelets and PRBCs before the operation. Fib fibrinogen, Hb hemoglobin, Plt platelets, APTT activated partial thromboplastin time, PT prothrombin time, FDP fibrin degradation products, AT antithrombin, FFP fresh frozen plasma, PRBCs packed red blood cells

necessary for the hemostasis. However, a more thorough and critical examination is required to prove the reliability of the device for the case with lowered fibrinogen concentration such as PPH.

A challenge with providing appropriate treatment for the patient with obstetric DIC is the difficulty of assessing the DIC [8]. Point-of-care viscoelastic testing, such as thromboelastography and thromboelastometry, has been recommended for making a treatment plan for the patient with obstetric DIC [9, 10]. However, substantial skill and experiences are required to correctly evaluate the result [11]. Furthermore, it was still difficult for us to select appropriate treatment based on the analysis of viscoelastic testing, specifically in the current case, where coagulability was modified by various treatments such as rFVIIa or antithrombin. Therefore, we were reluctant to use viscoelastic testing and instead made a treatment plan simply based on plasma fibrinogen value. This successfully resulted in the acceptable amount of bleeding at our hospital. Keeping enough fibrinogen value is a basis of obstetric DIC treatment because fibrinogen is a factor lying in the last stage of coagulation cascade [12, 13]. We think that the management system targeting fibrinogen is especially useful in countries such as Japan, where approximately half of the population goes through clinic-based delivery, and also where there is a shortage of obstetric anesthesiologists. However, other coagulation factors are still needed to form fibrin mesh, and more active supplementation of coagulation factors other than fibrinogen may be required according to the patient's condition [14], for instance, when bleeding cannot be controlled despite the maintained level of fibrinogen. In the present case, rFVIIa and antithrombin had been already administered at the previous institution, and furthermore, we administered FFP in addition to freeze-dried human fibrinogen. Thus, there is a probability that coagulation factors other than fibrinogen were sufficiently supplemented.

In obstetric DIC, activation of fibrinolysis is common. Since the suppression of hyperfibrinolysis has been suggested as the first step in a therapy algorithm for obstetric DIC, it is important to assess the fibrinolysis. Current evidence suggests that tranexamic acid (TXA) should be used as early as possible for women with established postpartum hemorrhage [15]. However, we did not administer TXA because it was more than 3 h after bleeding onset [16] and because rFVIIa had been administered at the previous institution. There have been some reports about embolism related to the administration of rFVIIa in combination with TXA [17, 18]. Therefore, we decided to transfuse FFP actively in order to maintain plasma fibrinogen value without administering TXA.

In conclusion, the portable fibrinogen measuring device was useful for the management of severe postpartum hemorrhage with complicated obstetric DIC. Further investigation should be made for the effective and enhanced use of the device in the treatment of obstetric DIC.

Abbreviations

PPH: Postpartum hemorrhage; DIC: Disseminated intravascular coagulation; rFVIIa: Recombinant activated factor VII; IU: International units; PRBCs: Packed red blood cells; FFP: Fresh frozen plasma; TXA: Tranexamic acid

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40981-021-00426-y>.

Additional file 1.

Acknowledgements

We would like to thank Sae Oshima (PhD, FHEA, Senior Lecturer of Corporate and Marketing Communications Faculty of Media and Communication | Bournemouth University) for the English language editing.

Authors' contributions

HS, TF, and MT participated in the anesthetic management. YH drafted the manuscript. HS and HO revised the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Please contact the author for data requests.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

A written informed consent was obtained from the patient for the publication of this case report.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Anesthesiology and Pain Medicine, Juntendo University Faculty of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan.

²Department of Anesthesiology and Pain Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan. ³Department of Anesthesiology, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.

Received: 6 February 2021 Revised: 28 February 2021

Accepted: 2 March 2021 Published online: 09 March 2021

References

1. Cortet M, Deneux-Tharoux C, Dupont C, Colin C, Rudigoz RC, Bouvier-Colle MH, et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. *Br J Anaesth*. 2012; 108:984–9.
2. Niepraschk-von DK, Bamberg C, Henkelmann A, Mickley L, Kufner L, Henrich W, et al. Predelivery maternal fibrinogen as a predictor of blood loss after vaginal delivery. *Arch Gynecol Obstet*. 2016;294:745–51.
3. Inoue R, Sumikura H, Kumagai A, Kato N, Makino S, Itakura A. Successful management of obstetric disseminated intravascular coagulation using a

- portable fibrinogen-measuring device. *J Obstet Gynaecol Res.* 2018;44:788–91.
4. Katz R, Efremov V, Mooney C, El-Khuffash A, Heaphy L, Cosgrave D, et al. Assessment of the reliability and validity of a novel point of care fibrinogen (F-Point) device against an industry standard at fibrinogen levels >2 g/L in non-haemorrhage scenarios. *Int J Obstet Anesth.* 2020;43:91–6.
 5. Solomon C, Collis RE, Collons PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. *Br J Anaesth.* 2012;109:851–63.
 6. Hayakawa M, Gando S, Ono Y, Mizugaki A, Katabami K, Maekawa K, et al. Rapid evaluation of fibrinogen levels using the CG02N whole blood coagulation analyzer. *SeminThromb Hemost.* 2015;41:267–71.
 7. Ogawa S, Tanaka K, Nakajima Y, Namayama Y, Takeshita J, Arai M, et al. Fibrinogen measurements in plasma and whole blood: a performance evaluation study of the dry-hematology system. *Anesth Analg.* 2015;120:18–25.
 8. Erez O. Disseminated intravascular coagulation in pregnancy - clinical phenotypes and diagnostic scores. *Thromb Res.* 2017;151:556–60.
 9. Snegovskikh D, Souza D, Walton Z, Dai F, Rachler R, Garay A, et al. Point-of-care viscoelastic testing improves the outcome of pregnancies complicated by severe postpartum hemorrhage. *J Clin Anesth.* 2018;44:50–6.
 10. Jackson DL, DeLoughery TG. Postpartum hemorrhage: management of massive transfusion. *Obstet Gynecol Surv.* 2018;73:418–22.
 11. Toffaletti JG, Buckner KA. Use of earlier-reported rotational thromboelastometry parameters to evaluate clotting status, fibrinogen, and platelet activities in postpartum hemorrhage compared to survey and intensive care patients. *Anesth Analg.* 2019;128:414–23.
 12. Seto S, Itakura A, Okagaki R, Suzuki M, Ishigara O. An algorithm for the management of coagulopathy from postpartum hemorrhage, using fibrinogen concentrate as first-line therapy. *Int J Obstet Anesth.* 2017;32:11–6.
 13. Collins PW, Bell SF, de Lloyd L, Collis RE. Management of postpartum haemorrhage; from research into practice, a narrative review of the literature and the Cardiff experience. *Int J Obstet Anesth.* 2019;37:106–17.
 14. McDonnell NJ, Browning R. How to replace fibrinogen in postpartum haemorrhage situations? (Hint: Don't use FFP!). *Int J Obstet Anesth.* 2018;33:4–7.
 15. Pacheco LD, Hankins GDV, Saad AF, Costantine MM, Chiossi G, Saade GR. Tranexamic acid for the management of obstetric hemorrhage. *Obstet Gynecol.* 2017;130:765–9.
 16. Brenner A, Ker K, Shakur-Still H, Roberts I. Tranexamic acid for post-partum haemorrhage: what, who and when. *Best Pract Res Clin Obstet Gynaecol.* 2019;61:66–74.
 17. Van Veen EJW, Monteban-Kooistra WE, Meertens JHJM, Ligtenberg JJM, Tulleken JE, Zijlstra JG. Recombinant human activated factor VII in postpartum hemorrhagic shock: the dark side. *Intensive Care Med.* 2008;34:211–2.
 18. Nohira T, Osakabe Y, Suda S, Takahashi C, Tanaka A, Ikeda T, et al. Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage. *J Obstet Gynaecol Res.* 2008;34:623–30.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)
